Clinical Study
Improving Blood Pressure Control in Patients with Diabetes Mellitus and High Cardiovascular Risk
Table 3
Further details of cardiovascular drugs and diabetes treatments.
| | Without diabetes | With diabetes | -value for Nifedipine | -value for Placebo comparison | | Nifedipine | Placebo | -value | Nifedipine | Placebo | -value | comparison |
| | Baseline |
| | Cardiovascular Drugs | | | | | | | | | | Beta-Blocker | 2583 (79%) | 2632 (80%) | — | 450 (79%) | 434 (80%) | — | 1.000 | .818 | | ACE-I or ARB | 664 (20%) | 678 (21%) | — | 195 (34%) | 202 (37%) | — | <.0001 | <.0001 | | Diuretic | 350 (11%) | 359 (11%) | — | 82 (15%) | 88 (16%) | — | .012 | <.0001 | | Any Blood | | | | | | | | | | Glucose | — | — | — | 434 (77%) | 419 (77%) | — | — | — | | Lowering Rx | | | | | | | | | | Insulin | — | — | — | 88 (16%) | 96 (18%) | — | — | — | | Metformin | — | — | — | 177 (31%) | 159 (29%) | — | — | — | | Sulfonylureas | — | — | — | 302 (53%) | 282 (52%) | — | — | — |
| | At any time |
| | Cardiovascular Drugs | | | | | | | | | | Beta-Blocker | 2868 (88%) | 2943 (89%) | .094 | 506 (89%) | 495 (91%) | .486 | .438 | .406 | | ACE-I or ARB | 1298 (40%) | 1583 (48%) | <.001 | 371 (65%) | 393 (72%) | .020 | <.0001 | <.0001 | | Diuretic | 1130 (35%) | 1256 (38%) | .004 | 261 (46%) | 287 (53%) | .031 | <.0001 | <.0001 |
|
|
